-
The fda has approved a higher dose of the rivastigmine transdermal system (13.3 mg/24 hours) for the treatment of Alzheimer's disease (AD). Lower-dose patches were previously approved for mild-to-moderate disease. Rivastigamine is a reversible acetylcholinesterase inhibitor. The transdermal system is marketed by Novartis as Exelon.
-
The impression is acute infero-posterior infarction, with possible lateral and right ventricular involvement. In most patients, the right coronary artery (RCA) supplies the right ventricle and posterior and inferior walls of the left ventricle.
-
In patients with multiple cardiovascular risk factors, daily treatment with n-3 fatty acids did not reduce cardiovascular mortality and morbidity.
-
The authors compared potential risk factors, clini-cal symptoms, diagnostic delay, and 3-month outcome between spontaneous internal carotid artery dissection (sICAD) and spontaneous vertebral artery dissection (sVAD).
-
Digoxin has no association with mortality in patients with heart failure in the AFFIRM study when bias is removed with a careful propensity-matched analysis.
-
Once-daily Tadalafil for ED: Efficacy and Safety; Psychological Disorders: How to Give Patients What They Want and What They Need; Reducing Stroke Risk After TIA or Minor Ischemic Stroke
-
A brief web intervention improved shared decision making regarding prostate cancer screening.
-
The updated practice guidelines for the treatment of atrial fibrillation include information on the newer treatments for rhythm control, treatment options to reduce atrial fibrillation complications, and updated anticoagulant management for thromboprophylaxis.
-
Stepwise risk factor-stratified screening in an elderly population using a handheld ECG device detected a significant number of patients with silent paroxysmal atrial fibrillation.
-
The authors conclude that in a large cohort of older patients with atrial fibrillation, hemorrhage is common during both the first 30 days and subsequent months of warfarin therapy, and is related to risk factors in the CHADS2 score and also to age.